Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The added value of 3.0 T quantitative multivoxel proton <sup>1</sup>H-MR spectroscopy in the diagnostic work-up of breast lesions.

European journal of radiology·2026
Same author

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.

Translational oncology·2026
Same author

Nutritional prehabilitation in head and neck cancer patients (PreHead) - A randomized controlled trial study protocol.

PloS one·2026
Same author

Prevalence of cardiac dysfunction and longitudinal changes in cardiac function after breast cancer treatment with chemotherapy with/without radiation therapy compared with controls.

Breast (Edinburgh, Scotland)·2026
Same author

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125].

European journal of cancer (Oxford, England : 1990)·2026
Same author

No Evidence of Microsatellite Instability in Head and Neck Squamous Cell Carcinoma of Non-Smokers and Non-Drinkers.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·2026

Related Experiment Video

Updated: Jun 25, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.

V D de Jager1, B N Cajiao Garcia1, C C H J Kuijpers2

  • 1Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

European Journal of Cancer (Oxford, England : 1990)
|May 24, 2024
PubMed
Summary

Predictive biomarker testing rates for non-small cell lung cancer (NSCLC) in the Netherlands varied significantly by biomarker type. Guideline-adherent testing was associated with patient demographics, clinical factors, and healthcare setting, indicating a need for care optimization.

Keywords:
Guideline-adherenceNSCLCPredictive biomarker testingReal-world data

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Related Experiment Videos

Last Updated: Jun 25, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Public Health

Background:

  • Predictive biomarker testing is crucial for guiding non-small cell lung cancer (NSCLC) treatment decisions, as mandated by international guidelines.
  • Understanding current testing rates and associated factors is essential for improving patient care and adherence to clinical recommendations.

Purpose of the Study:

  • To determine guideline-adherent predictive biomarker testing rates in the Netherlands for patients diagnosed with metastatic non-squamous NSCLC in 2019.
  • To investigate the influence of demographic, clinical, and environmental factors on the adherence to guideline-based biomarker testing.

Main Methods:

  • Integration of clinical data from the Netherlands Cancer Registry with pathology reports from the Dutch Nationwide Pathology Databank.
  • Extraction of data on sample type, diagnosis, and molecular testing status for predictive biomarkers.
  • Analysis of a cohort comprising all patients diagnosed with metastatic non-squamous NSCLC in the Netherlands in 2019.

Main Results:

  • Overall molecular testing rates for non-fusion biomarkers ranged from 73.9% to 89.0%, while rates for fusion-drivers ranged from 12.6% to 63.9%.
  • Guideline-adherent testing for EGFR, KRAS, and ALK was observed in 85.2% of patients, with regional variations.
  • Factors associated with higher guideline-adherent testing included younger age, female sex, adenocarcinoma diagnosis, availability of histological material, metastatic disease stage, academic center diagnosis, and region of residence.

Conclusions:

  • Significant disparities in predictive biomarker testing rates for NSCLC patients highlight the need for optimizing the chain-of-care.
  • Addressing identified demographic, clinical, and regional factors is crucial for ensuring equitable and adequate patient care.